Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
New structural insights into drug resistance with Salipro®
2025-01-24
A recent study published in The EMBO Journal has shed light on how Salipro®-embedded ABCB1 recognizes and transports a wide range of substrates.
Role of Salipro® technology: Our Salipro® technology was pivotal in stabilizing ABCB1 in native lipid environments for native-mass spectrometry (nMS), ATPase activity assays and cryoEM.
Superior activity and stability: The Salipro®-ABCB1 particles demonstrated greater ATPase activity and a more homogenous mass distribution - compared to traditional nanodisc reconstitution methods.
High-resolution structural insights: The 3D structures of lipid-embedded human Salipro®-ABCB1 revealed the dynamic structural changes and binding site plasticity that ABCB1 undergoes when interacting with various substrates and inhibitors.
This structural and functional work unlocked with Salipro® deepens our understanding of ABCB1's mechanisms and opens new avenues for developing new drugs to bypass multidrug resistance.
Congratulations to Amer Alan and the entire research team for this contribution to understanding drug interactions and resistance mechanisms!
Read the full study here:
D. Kurre, et al., Structural insights into binding-site access and ligand recognition by human ABCB1. EMBO J. (2025).
Salipro announces a new research collaboration
2025-01-17
New Year, New Collaboration!
We’re excited to kick off the new year with a new research collaboration! With the Salipro® platform, these projects focus on the stabilization of the most challenging drug targets in the field, aiming to transform difficult membrane proteins into opportunities for therapeutic advancements.
We look forward to the advancements that these projects will bring in this year committed to our mission to make the undruggable druggable!
Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patents in Australia and Singapore
2024-12-05
Salipro Biotech strengthens its global intellectual property portfolio with granted patents in Singapore and Australia, protecting its proprietary Salipro® platform technology to enable the development of therapeutics against challenging drug targets.
Stockholm, Sweden, December 5, 2024 – Salipro Biotech AB, a Swedish biotechnology company focused on advancing drug discovery for challenging drug targets, today announced the issuance of granted patents in both Singapore and Australia for its Salipro® platform technology, a novel and proprietary method for directly isolating and purifying native membrane proteins, which are important targets for many therapeutic drugs. The Salipro® platform enables entirely novel drug discovery programs, including antibody discovery, small molecule drug screening and structure-based drug design.
The patents, entitled “Production of Salipro® Particles” (Australian Patent No. 2020257991; Singaporean Patent No. 11202111111U), cover processes implemented in the Salipro® platform and represent an important milestone that strengthens Salipro Biotech’s position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.
Access the full press release.